直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Article

Claim Construction

2016

ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators, Second Edition

By Mark J. Feldstein, Ph.D.; Krista E. Bianco

Claim construction is the process in which courts interpret the meaning and scope of a patent's claims. Since the claims "define the invention to which the patentee is entitled the right to exclude," construing the claims can be a critical step in determining the outcome of almost all patent litigations. In fact, the first step of any infringement or validity analysis is to determine the meaning of the claims (i.e., what the claims encompass and what they do not). Only after the boundaries of the claims have been determined can a judge or jury decide whether the allegedly infringing product or process falls within the scope of the patentee's claims, whether the claims are adequately described in the specification, or whether the claims are invalid in view of the prior art. From a practical standpoint, once the scope of the patentee's rights has been determined, the question of infringement can often be resolved without trial, often by agreement of the parties or on summary judgment.

This chapter begins by setting forth the general principles of the claim construction analysis. Once the basic rules for interpreting the meaning of the claims have been explained, this chapter addresses the timing and procedural aspects of the claim construction analysis. Mark J. Feldstein, Ph.D. discusses various strategic considerations the parties to an Abbreviated New Drug Application (ANDA) case should address once the claims have been construed.

 

Tags

claim construction, infringement

Related Practices

Global IP Enforcement, Litigation, and Trials

Branded Hatch-Waxman (ANDA) Litigation and Trials

Related Professionals

Mark J. Feldstein, Ph.D.
Partner
Washington, DC
+1 202 408 4092
Email

Originally printed in ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators, Second Edition in 2016. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm’s clients.

Related Insights

Federal Circuit IP Blog

Federal Circuit Affirms Indefiniteness of the Term “About”

June 10, 2026

Federal Circuit IP Blog

Federal Circuit Reinforces Injury-in-Fact Requirement in Appeals from Post-Grant Proceedings

June 10, 2026

Federal Circuit IP Blog

Spotlight on Upcoming Oral Arguments – June 2026

June 8, 2026

European IP Blog

UPC Central Division Revokes Patent Covering Covid-19 Treatment Remdesivir

8 June 2026

Articles

Article_D.-Mass-Patent-Litigation-Update-October-2024

D. Mass. Patent Litigation Update: April 2026

June 1, 2026

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP